UNICREDIT BANK/CALL/NOVARTIS N/110/0.1/18.12.24 | Market Closed - Bid/Ask 01:40:27 2024-05-21 pm EDT | After market 03:59:09 pm | |||
| 0.078 EUR | +11.43% |
|
0.086 | +10.26% |
| 1 month | +116.67% | ||
| 3 months | +23.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVARTIS AG
| Date | Price | Change |
|---|---|---|
| 24-05-21 | 0.078 | +11.43% |
| 24-05-20 | 0.07 | 0.00% |
| 24-05-17 | 0.07 | +7.69% |
| 24-05-16 | 0.065 | -13.33% |
| 24-05-15 | 0.075 | -3.85% |
Real-time Boerse Frankfurt Warrants
Last update May 21, 2024 at 01:40 pm EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVARTIS AG |
| Issuer | 
UniCredit
|
| WKN | HD21N3 |
| ISIN | DE000HD21N32 |
| Date issued | 2024-01-23 |
| Strike | 110 CHF |
| Maturity | 2024-12-18 (211 Days) |
| Parity | 10 : 1 |
| Emission price | 0.17 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.14 € |
|---|---|
| Lowest since issue | 0.03 € |
| Spread | 0.017 € |
| Spread % | 18.09% |
Company Profile
Novartis AG is one of the world's leaders in the design, manufacturing, and marketing of pharmaceutical products. Net sales (excluding discontinued operations) break down by therapeutic area as follows:
- oncology (29.9%);
- immunology (17.2%);
- cardiovascular, renal and metabolic diseases (14.1%);
- neuroscience (8.9%).
The remaining net sales (29.9%) are from contract manufacturing of pharmaceutical products.
At the end of 2023, Novartis AG had 33 production sites worldwide.
Net sales are distributed geographically as follows: Europe (33%), the United States (39.5%), Asia/Africa/Australasia (20.5%), Canada and Latin America (7%).
Sector
-
Consensus: Novartis AG
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
103.1
USD
Average target price
108
USD
Spread / Average Target
+4.72%
- Stock Market
- Warrants
- Warrant